Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 28

1.
2.

Pimavanserin.

Hunter NS, Anderson KC, Cox A.

Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001.

PMID:
26744739
3.

New clinical trials for nonmotor manifestations of Parkinson's disease.

Schrag A, Sauerbier A, Chaudhuri KR.

Mov Disord. 2015 Sep 15;30(11):1490-504. doi: 10.1002/mds.26415. Review.

PMID:
26371623
4.

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ.

J Am Med Dir Assoc. 2015 Oct 1;16(10):898.e1-7. doi: 10.1016/j.jamda.2015.06.021. Epub 2015 Aug 1.

5.

Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.

Cummings J, Zhong K.

Clin Pharmacol Ther. 2015 Nov;98(5):483-5. doi: 10.1002/cpt.190. Epub 2015 Aug 31. Review.

PMID:
26206713
7.

Comprehensive treatment of dementia with Lewy bodies.

Boot BP.

Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

8.

(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.

Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):1053-6. doi: 10.1016/j.bmcl.2015.01.017. Epub 2015 Jan 20.

PMID:
25655720
9.

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Broadstock M, Ballard C, Corbett A.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):779-86. doi: 10.1586/17512433.2014.966814. Epub 2014 Oct 10. Review.

PMID:
25301532
10.

Treating psychosis in movement disorder patients: a review.

Borek LL, Friedman JH.

Expert Opin Pharmacother. 2014 Aug;15(11):1553-64. doi: 10.1517/14656566.2014.918955. Epub 2014 May 20. Review.

PMID:
24846479
11.

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H.

Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review.

12.

Treatment of psychosis and dementia in Parkinson's disease.

Goldman JG, Holden S.

Curr Treat Options Neurol. 2014 Mar;16(3):281. doi: 10.1007/s11940-013-0281-2.

13.

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.

Meltzer HY, Roth BL.

J Clin Invest. 2013 Dec;123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2. Review.

14.

Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.

Kingwell K.

Nat Rev Neurol. 2013 Dec;9(12):658. doi: 10.1038/nrneurol.2013.233. Epub 2013 Nov 19. No abstract available.

PMID:
24247322
15.

Pimavanserin as treatment for Parkinson's disease psychosis.

Fox SH.

Lancet. 2014 Feb 8;383(9916):494-6. doi: 10.1016/S0140-6736(13)62157-1. Epub 2013 Nov 1. No abstract available.

PMID:
24183566
16.

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C.

Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28.

PMID:
24183563
17.

Pimavanserin for the treatment of Parkinson's disease psychosis.

Friedman JH.

Expert Opin Pharmacother. 2013 Oct;14(14):1969-75. doi: 10.1517/14656566.2013.819345. Review.

PMID:
24016069
18.

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.

Hubbard D, Hacksell U, McFarland K.

Behav Pharmacol. 2013 Oct;24(7):628-32. doi: 10.1097/FBP.0b013e3283656db6.

PMID:
23969614
19.

Is there room for non-dopaminergic treatment in Parkinson disease?

Lieberman A, Krishnamurthi N.

J Neural Transm (Vienna). 2013 Feb;120(2):347-8. doi: 10.1007/s00702-012-0946-0. Epub 2012 Dec 16.

PMID:
23242741
20.

Is there room for new non-dopaminergic treatments in Parkinson's disease?

Pilleri M, Koutsikos K, Antonini A.

J Neural Transm (Vienna). 2013 Feb;120(2):349-52. doi: 10.1007/s00702-012-0947-z. Epub 2012 Dec 11.

PMID:
23229903
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk